JP2009540000A - 化学療法により誘導された貧血の治療のための化合物および方法 - Google Patents

化学療法により誘導された貧血の治療のための化合物および方法 Download PDF

Info

Publication number
JP2009540000A
JP2009540000A JP2009515515A JP2009515515A JP2009540000A JP 2009540000 A JP2009540000 A JP 2009540000A JP 2009515515 A JP2009515515 A JP 2009515515A JP 2009515515 A JP2009515515 A JP 2009515515A JP 2009540000 A JP2009540000 A JP 2009540000A
Authority
JP
Japan
Prior art keywords
amino
alkyl
hydroxy
carbonyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540000A5 (https=
Inventor
シーリー，トッド，ダブリュ．
リュー，デビッド，ワイ．
クラウス，ステファン，ジェイ．
Original Assignee
ファイブローゲン、インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブローゲン、インコーポレーテッド filed Critical ファイブローゲン、インコーポレーテッド
Publication of JP2009540000A publication Critical patent/JP2009540000A/ja
Publication of JP2009540000A5 publication Critical patent/JP2009540000A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009515515A 2006-06-15 2007-06-14 化学療法により誘導された貧血の治療のための化合物および方法 Pending JP2009540000A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/455,200 US7713986B2 (en) 2006-06-15 2006-06-15 Compounds and methods for treatment of chemotherapy-induced anemia
PCT/US2007/014077 WO2007146425A2 (en) 2006-06-15 2007-06-14 Compounds and methods for treatment of chemotherapy-induced anemia

Publications (2)

Publication Number Publication Date
JP2009540000A true JP2009540000A (ja) 2009-11-19
JP2009540000A5 JP2009540000A5 (https=) 2010-07-29

Family

ID=38809393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515515A Pending JP2009540000A (ja) 2006-06-15 2007-06-14 化学療法により誘導された貧血の治療のための化合物および方法

Country Status (3)

Country Link
US (2) US7713986B2 (https=)
JP (1) JP2009540000A (https=)
WO (1) WO2007146425A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8415388B2 (en) * 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
BRPI0707302B8 (pt) * 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
WO2009073669A1 (en) * 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US8217043B2 (en) * 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
US20140057941A1 (en) * 2011-01-13 2014-02-27 Kin-Hung (Peony) Yu Methods For Increasing Mean Corpuscular Volume
US20140171465A1 (en) * 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013070908A1 (en) * 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN119139302A (zh) * 2023-05-17 2024-12-17 珐博进(中国)医药技术开发有限公司 [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸（罗沙司他）用于治疗化疗诱导的贫血（cia）

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
JP2005524612A (ja) * 2001-12-06 2005-08-18 ファイブローゲン、インコーポレーテッド 内因性エリスロポエチン（ｅｐｏ）を増加させる方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
MX2007016160A (es) * 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524612A (ja) * 2001-12-06 2005-08-18 ファイブローゲン、インコーポレーテッド 内因性エリスロポエチン（ｅｐｏ）を増加させる方法
JP2005526010A (ja) * 2001-12-06 2005-09-02 ファイブローゲン、インコーポレーテッド 低酸素誘導性因子（ＨＩＦ）−αの安定化
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5009011452; ＧＬＡＳＰＹ　Ｊ　Ａ: ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＥＭＥＲＧＩＮＧ　ＤＲＵＧＳ Ｖ１０　Ｎ３, 2005, Ｐ５５３-５６７, ＡＳＨＬＥＹ　ＰＵＢＬＩＣＡＴＩＯＮＳ *
JPN6012045650; Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ ３４，　３, 1998, ｐ．３６４-３６７ *

Also Published As

Publication number Publication date
WO2007146425A2 (en) 2007-12-21
US7713986B2 (en) 2010-05-11
US20100204269A1 (en) 2010-08-12
US20070292433A1 (en) 2007-12-20
WO2007146425A3 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
JP2009540000A (ja) 化学療法により誘導された貧血の治療のための化合物および方法
JP5390184B2 (ja) 貧血の改良された治療方法
JP5410751B2 (ja) がん治療のための化合物および方法
JP2009540004A (ja) 癌の貧血の治療のためのｈｉｆヒドロキシラーゼ阻害剤
US20070259960A1 (en) Compounds and methods for treatment of stroke
US20070042937A1 (en) Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US20110263642A1 (en) Methods for treatment of multiple sclerosis
US20140309256A1 (en) Therapeutic Method
US20070185045A1 (en) Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
HK1117422B (en) Use of hif 1alfa modulators for treatment of cancer
WO2010024911A1 (en) Methods for increasing neurogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130521